Boceprevir and Treatment of Chronic Hepatitis C

Paul Y. Kwo

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

The addition of boceprevir to peginterferon and ribavirin has improved sustained response rates markedly. Boceprevir is effective in treatment naïve, relapsers, partial responders, and null responders. Those with advanced fibrosis require 44 weeks of boceprevir therapy after a 4-week peg/ribavirin lead-in. The main side effect with boceprevir is anemia and ribavirin dose reduction is an effective strategy. This review examines the current treatment paradigm of boceprevir-based treatment of chronic hepatitis C, examining treatment paradigms, predictors of response, futility rules, as well as preliminary results from studies examining boceprevir efficacy in additional populations. Further follow-up in these cohorts will be required.

Original languageEnglish (US)
Pages (from-to)63-72
Number of pages10
JournalClinics in Liver Disease
Volume17
Issue number1
DOIs
StatePublished - Feb 1 2013

Fingerprint

Chronic Hepatitis C
Ribavirin
Medical Futility
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
Anemia
Fibrosis
Population

Keywords

  • Boceprevir
  • Hepatitis C
  • Peginterferon
  • Ribavirin

ASJC Scopus subject areas

  • Hepatology

Cite this

Boceprevir and Treatment of Chronic Hepatitis C. / Kwo, Paul Y.

In: Clinics in Liver Disease, Vol. 17, No. 1, 01.02.2013, p. 63-72.

Research output: Contribution to journalReview article

Kwo, Paul Y. / Boceprevir and Treatment of Chronic Hepatitis C. In: Clinics in Liver Disease. 2013 ; Vol. 17, No. 1. pp. 63-72.
@article{d07aebb019584576a25adc54e6b1d31c,
title = "Boceprevir and Treatment of Chronic Hepatitis C",
abstract = "The addition of boceprevir to peginterferon and ribavirin has improved sustained response rates markedly. Boceprevir is effective in treatment na{\"i}ve, relapsers, partial responders, and null responders. Those with advanced fibrosis require 44 weeks of boceprevir therapy after a 4-week peg/ribavirin lead-in. The main side effect with boceprevir is anemia and ribavirin dose reduction is an effective strategy. This review examines the current treatment paradigm of boceprevir-based treatment of chronic hepatitis C, examining treatment paradigms, predictors of response, futility rules, as well as preliminary results from studies examining boceprevir efficacy in additional populations. Further follow-up in these cohorts will be required.",
keywords = "Boceprevir, Hepatitis C, Peginterferon, Ribavirin",
author = "Kwo, {Paul Y.}",
year = "2013",
month = "2",
day = "1",
doi = "10.1016/j.cld.2012.09.005",
language = "English (US)",
volume = "17",
pages = "63--72",
journal = "Clinics in Liver Disease",
issn = "1089-3261",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Boceprevir and Treatment of Chronic Hepatitis C

AU - Kwo, Paul Y.

PY - 2013/2/1

Y1 - 2013/2/1

N2 - The addition of boceprevir to peginterferon and ribavirin has improved sustained response rates markedly. Boceprevir is effective in treatment naïve, relapsers, partial responders, and null responders. Those with advanced fibrosis require 44 weeks of boceprevir therapy after a 4-week peg/ribavirin lead-in. The main side effect with boceprevir is anemia and ribavirin dose reduction is an effective strategy. This review examines the current treatment paradigm of boceprevir-based treatment of chronic hepatitis C, examining treatment paradigms, predictors of response, futility rules, as well as preliminary results from studies examining boceprevir efficacy in additional populations. Further follow-up in these cohorts will be required.

AB - The addition of boceprevir to peginterferon and ribavirin has improved sustained response rates markedly. Boceprevir is effective in treatment naïve, relapsers, partial responders, and null responders. Those with advanced fibrosis require 44 weeks of boceprevir therapy after a 4-week peg/ribavirin lead-in. The main side effect with boceprevir is anemia and ribavirin dose reduction is an effective strategy. This review examines the current treatment paradigm of boceprevir-based treatment of chronic hepatitis C, examining treatment paradigms, predictors of response, futility rules, as well as preliminary results from studies examining boceprevir efficacy in additional populations. Further follow-up in these cohorts will be required.

KW - Boceprevir

KW - Hepatitis C

KW - Peginterferon

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=84870028430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870028430&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2012.09.005

DO - 10.1016/j.cld.2012.09.005

M3 - Review article

C2 - 23177283

AN - SCOPUS:84870028430

VL - 17

SP - 63

EP - 72

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 1

ER -